Skip to main content

Table 2 Clinically significant exacerbations, by baseline characteristic subgroup

From: Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials

  Odds ratio, mepolizumab/placebo (95% CI) Number of patients
Mepolizumab Placebo
Annualised rate of exacerbations requiring an ED visit/hospitalisation
 Age at asthma onset
  ITT population 0.36 (0.20, 0.67) 468 468
  < 18 years 0.23 (0.08, 0.69) 132 122
  18–< 40 years 0.21 (0.05, 0.83) 173 172
  ≥ 40 years 0.51 (0.19, 1.35) 162 174
 Lung function
  ITT population 0.36 (0.20, 0.67) 468 468
  ≤ 60% predicted FEV1 0.41 (0.19, 0.86) 245 244
  > 60–80% predicted FEV1 Non-est* n/a n/a
  ≥ 80% predicted FEV1 Non-est* n/a n/a
% patients with no clinically significant exacerbations
 Age at asthma onset
 ITT population 3.03 (2.25, 4.07) 468 468
  < 18 years 2.97 (1.67, 5.26) 132 122
 18–< 40 years 3.19 (1.90, 5.36) 173 172
 ≥ 40 years 3.32 (1.98, 5.55) 162 174
 Lung function
  ITT population 3.03 (2.25, 4.07) 468 468
  ≤ 60% predicted FEV1 2.67 (1.79, 3.98) 245 244
  > 60–80% predicted FEV1 3.18 (1.92, 5.28) 177 177
  ≥ 80% predicted FEV1 4.90 (1.54, 15.62) 46 47
  1. CI confidence interval, ED emergency department, FEV1 forced expiratory volume in 1 s, ITT intent-to-treat, n/a not applicable, non-est non-estimable
  2. aThe odds ratio was non-estimable for this subgroup owing to insufficient data to perform modelling